Literature DB >> 12650750

Clinical use of polyethylene glycols as marker substances and determination in urine by liquid chromatography.

Gisela Gauchel1, Bernd Huppertz, Heribert Feiertag, Ruprecht Keller.   

Abstract

Adulteration of samples is a serious problem in the analysis of drugs of abuse. One of the most frequent methods is substitution of urines by "clean" urines to gain false-negative results in laboratory tests for drugs of abuse. One way to approach this problem may be to label the patient's urine with marker substances which are given orally prior to the delivery of urine. This concept is based on methods for determining malabsorption in pediatric medicine. We report a protocol for evaluating low-molecular-mass polyethylene glycols as enteral labelling marker substances. For monitoring renal excretion of the ingested polyethylene glycols we have developed and optimised an isocratic reversed-phase high-performance liquid chromatographic method with automatic sample cleanup by column switching in the back-flush technique and with RI detection. The chromatographic procedure is simple, reliable and rapid, allowing a high sample throughput for routine screening.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12650750     DOI: 10.1016/s1570-0232(02)00925-x

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  2 in total

1.  The Urine Marker Test: An Alternative Approach to Supervised Urine Collection for Doping Control.

Authors:  Anne-Marie Elbe; Stine Nylansted Jensen; Peter Elsborg; Monika Wetzke; Getachew A Woldemariam; Bernd Huppertz; Ruprecht Keller; Anthony W Butch
Journal:  Sports Med       Date:  2016-01       Impact factor: 11.136

2.  Need and utility of a polyethylene glycol marker to ensure against urine falsification among heroin users.

Authors:  Jermaine D Jones; Jared J Atchison; Gabriela Madera; Verena E Metz; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2015-05-27       Impact factor: 4.492

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.